We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Clotting Initiator Blamed for Hepatitis Liver Damage

By Biotechdaily staff writers
Posted on 14 Jul 2003
Researchers have identified a protein that triggers the formation of blood clots in the minute blood vessels of the liver in patients with chronic viral hepatitis and may be the cause of the damage caused to the liver during the infection.

Investigators at the University of Toronto (Canada) genetically engineered a line of mice lacking the gene for production of fg12/fibroleukin prothrombinase. More...
When infected with a mouse hepatitis (corona) virus, these mice failed to generate blood clotting and 40% of the mice were still alive 14 days after being infected. Normal mice infected with the virus experienced blood clotting and died within four to seven days of hepatitis infection.

In addition to the tests on mice, liver biopsies from 23 human patients with severe chronic hepatitis B and 13 patients with minimal chronic hepatitis were examined to determine their fg12/fibroleukin prothombinase concentrations and the severity of clotting in their liver tissue. The results, published in the July 1, 2003, issue of the Journal of Clinical Investigation, showed that patients with severe chronic hepatitis expressed fgl2 protein in their livers in association with fibrin clots resulting in liver cell death. Patients with mild chronic hepatitis B had no evidence of fgl2 expression or clotting within their livers.

"This offers new hope to patients by paving the way for future therapies that will change the course of hepatitis,” said senior author Dr. Philip Marsden, professor of medicine at the University of Toronto. "Our work represents an innovative new approach to combating viral disease. Therapies to date have focused on getting rid of the virus, but this work points the way to blocking the damage the virus does.”




Related Links:
University of Toronto

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.